Entering text into the input field will update the search result below

Myovant: Catalysts Powering More Upside

Jan. 02, 2022 1:45 PM ETMyovant Sciences Ltd. (MYOV)PFE11 Comments
BioSci Capital Partners profile picture
BioSci Capital Partners


  • Due to the combination of a market downturn and other issues, Myovant shares depreciated substantially.
  • Nevertheless, there are powerful fundamental advancements that signal much more upsides going into New Year 2022.
  • The partial clinical hold for the SERENE trial is recently removed by the FDA. Orgovyx is poised to gain approval in Europe by mid-year 2022.
  • I do much more than just articles at Integrated BioSci Investing: Members get access to model portfolios, regular updates, a chat room, and more. Learn More »

Smiling female doctor talking to woman in hospital

The Good Brigade/DigitalVision via Getty Images

Myovant Sciences

The need for patience if big profits are to be made from investment. - Phillip Fisher (Warren Buffett's Mentor)

In biotech investing, when a company enters its commercialization phase the stock tends to trade with

Thanks for reading! To read the full article, CLICK HERE. To get the latest articles, please hit the orange “Follow” button on top.

Be sure to check out our private investment research community, Integrated BioSci Investing.

Dr. Tran's analyses are the best in the biotech sphere, well worth the price of subscription.

Very professional, extremely knowledgeable and very honest … I would highly recommend this service and his stock picks have been very profitable.

Simply put, this is worth every penny. Just earlier today, one of the companies recommended by Dr. Tran got acquired for a nice 50% premium.

Click here for a FREE TRIAL.

This article was written by

BioSci Capital Partners profile picture
As an astute devotee of Warren Buffet, Ben Graham, Phillip Fisher, Sir John Templeton, and Peter Lynch, Dr. Harvey devoured any resources/books on these gurus to learn their craft for over two decades. In the process, he refined their investment approaches specifically to biotech and founded Integrated BioSci Investing: The Number #1 Biotech Service for Long-Term Growth Investing and Power Catalyst Trading.  Since inception, our flagship portfolio has delivered over 31.23% annual average (i.e. 187.39% for roughly six years). As you can appreciate, we’re adept at assisting and serving institutional/retail investors/traders who are looking for alpha. Dividend investors wanting to boost your return can also benefit greatly from our investment research. We currently have over 20 docs in our service for us to tap into their clinical insight for your gains. Check out some of our binary event forecasts that lead to meteoric gain like the 359% single-day pop from Madrigal Pharmaceuticals (MDGL)’s NASH data release. During his training at the world-renown Columbia University, Harvey Tran, M.D., M.S., developed a passion/edge for analyzing the intricacies of various preclinical/clinical studies, biostatistics, and science/medicine. Importantly, it allowed the physician-scientist Harvey to realize the internal working of various therapeutic in-development that the market tends to overlook. In recent years, Dr. Harvey founded and led two healthcare roll-up companies. The endeavor helped him gain deep insight into the inner working of a corporate board. His experience as a consultant to common/professional investors and institutions gave him a huge advantage in biotech analysis. The combination of elite training and a passion for biotech provided Dr. Harvey with an aptitude for delivering highly accurate clinical data forecasting that is crucial to picking winning biotech investments for you.Follow us for the latest research. And, take our FREE 2-week trial to Integrated BioSci Investing to start your winning process now!Check out Dr. Harvey’s LinkTree for his complete experience. You can make your one good decision a year as Mr. Buffett recommended by checking out  Integrated BioSci Investing!

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

As a medical doctor/market expert, I'm not a registered investment advisor. Despite that I strive to provide the most accurate information, I neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. I reserve the right to make any investment decision for myself and my affiliates pertaining to any security without notification except where it is required by law. I'm also NOT responsible for the action of my affiliates. The thesis that I presented may change anytime due to the changing nature of information itself. Investing in stocks and options can result in a loss of capital. The information presented should NOT be construed as recommendations to buy or sell any form of security. My articles are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your action. You should also consult with your own financial advisor for specific guidance, as financial circumstances are individualized. That aside, I'm not giving you professional medical advice. Before embarking on any health-changing behavior, make sure you consult with your own doctor.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (11)

This is why I'm considering just bailing out of the biotech sector altogether and never looking back. It seems no matter how promising a pipeline might be, the majority of biotechs just keep plummeting. I recently looked at my bio gains versus losses, and it is my worst performing sector by far over the last decade. The rare buyout seems to be the only way to capitalize on owning any bio shares and that is a crapshoot.
It seems to be going the other way. It has great fundamentals compared to another take over play AUPH but has underperformed. Based on my observations in the past these moves are related to immediate take over. AIMT had a similar past under similar market conditions.
Short interest is high at 13.7% given institutions have 85% of the float. It's the ultimate shakedown cannot succeed if mkt conditions are let to improve. Despite FOMC and anticipated rate hikes there is enough liquidity in the mkt. FOMC is still pumping money into the repo mkt while "talking" about balance sheet reduction.
Inflation is high but it's a global phenomenon. Lot of countries around the world are still struggling with COVID-19. FOMC isn't foolish nor is it on am island to disrupt the world economies when they are looking to start or stabilize their economies.
Wall St and Pundits on CNBC and the idiot traders they parade all day. MYOV and rest may have been trades in the past at this stage with 2 SoC possibilities and the magnitude of importance of Myfembree winning approval in Contraceptive mkt is enormous. Dumb day traders parading their trades daily don't understand the magnitude they are momentum chasers. Investors should be lapping up on MYOV with or without take over possibilities. Even if rates go up to 3.5% by end of 2024. MYOV has sufficient cash to reach profitability. The growth in both segments is likely to continue to be 30-40% Q/Q for next 8-12 Qtrs. 11K patients with 100K on ADT and expected to add 300K. The head room for growth is tremendous.
Anyway dumb to ignore the value here. Insanity prevails because CNBC isn't teaching investing.
you make a lot of sense but for as an investor i need to have some idea of market share achievable and the size of the markets, and what peak sales could be until then its all noise to me.
@john boy You need to understand Pfizer's marketing strategy. They will make both drugs SoC.
And today SVB downgraded to lot perform. So which fake media do you believe in? MYOV is worth a lot higher possibly 3x its current price ir higher. Will the long investors really get what it's worth?
Too many games being played and dumb money keeps chasing the wrong stocks so I think. I am sure they must think I am crazy to load up on MYOV..
its going to be mid 2023 before this company is worth their current share price.
LifeSciObserver profile picture
@john boy could you please tell me why? Because relugolix is a really great drug.
liegh aulper profile picture
Interesting, that you did not mention that sumitoma, their parent and biggest shareholder, has been buying stock. Their last purchase being in the low 20’s. In addition, S has a habit of buying out their ..ant subsidiaries.
What's not to like here? Two newly approved, decent sized indications, with more to come (we hope), and only $1.5B MC. Solid financial backing in Sumitomo and an aggressive and competent partner in PFE.
BioSci Capital Partners profile picture
@tkarl Exactly. Great medicines and strong financial support. It's just likely that the 2021 Biotech Bear market cause this fundamentally robust stock to trade much lower than its true worth.

Dr. Harvey Tran
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.